InsiderClue
Stocks · Health care · Pharmaceutical Preparations

CytomX Therapeutics, Inc.

CTMX Clue Score46
United States Fiscal year ends December CIK 0001501989
$2.57 +4.05% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.57 −48.39% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue12.8Operating income−59.6Net income−58.9Fiscal year 2017Revenue71.6 +457.6%Operating income−46.3Net income−43.1Fiscal year 2018Revenue59.5 −16.9%Operating income−77.9Net income−84.6Fiscal year 2019Revenue26.9 −54.8%Operating income−141.5Net income−132.8EPS, diluted−2.93Fiscal year 2020Revenue68.4 +154.4%Operating income−80.5Net income−64.8EPS, diluted−1.40Fiscal year 2021Revenue37.3 −45.5%Operating income−116.0Net income−115.9EPS, diluted−1.81Fiscal year 2022Revenue53.2 +42.5%Operating income−101.3Net income−99.3EPS, diluted−1.51Fiscal year 2023Revenue101.2 +90.4%Operating income−6.5Net income−0.6EPS, diluted−0.01Fiscal year 2024Revenue138.1 +36.4%Operating income25.0Net income31.9EPS, diluted0.38Fiscal year 2025Revenue76.2 −44.8%Operating income−22.4Net income−17.4 −154.5%EPS, diluted−0.15
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 12.8 71.6 59.5 26.9 68.4 37.3 53.2 101.2 138.1 76.2
Growth +457.6% −16.9% −54.8% +154.4% −45.5% +42.5% +90.4% +36.4% −44.8%
Operating income −59.6 −46.3 −77.9 −141.5 −80.5 −116.0 −101.3 −6.5 25.0 −22.4
Net income −58.9 −43.1 −84.6 −132.8 −64.8 −115.9 −99.3 −0.6 31.9 −17.4
Growth −154.5%
EPS, diluted n/a n/a n/a −2.93 −1.40 −1.81 −1.51 −0.01 0.38 −0.15

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Operating margin−463.9%Net margin−458.5%Free cash flow margin−32.8%Fiscal year 2017Operating margin−64.6%Net margin−60.2%Free cash flow margin235.7%Fiscal year 2018Operating margin−130.9%Net margin−142.2%Free cash flow margin−133.3%Fiscal year 2019Operating margin−525.9%Net margin−493.7%Free cash flow margin−535.2%Fiscal year 2020Operating margin−117.7%Net margin−94.7%Free cash flow margin4.3%Fiscal year 2021Operating margin−311.0%Net margin−310.5%Free cash flow margin−323.3%Fiscal year 2022Operating margin−190.6%Net margin−186.8%Free cash flow margin−211.7%Fiscal year 2023Operating margin−6.4%Net margin−0.6%Free cash flow margin−56.2%Fiscal year 2024Operating margin18.1%Net margin23.1%Free cash flow margin−62.7%Fiscal year 2025Operating margin−29.3%Net margin−22.8%Free cash flow margin−99.5%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −463.9% −64.6% −130.9% −525.9% −117.7% −311.0% −190.6% −6.4% 18.1% −29.3%
Net margin −458.5% −60.2% −142.2% −493.7% −94.7% −310.5% −186.8% −0.6% 23.1% −22.8%
Free cash flow margin −32.8% 235.7% −133.3% −535.2% 4.3% −323.3% −211.7% −56.2% −62.7% −99.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−2.0Capital expenditure−2.2Free cash flow−4.2Fiscal year 2017Operating cash flow170.4Capital expenditure−1.6Free cash flow168.8Fiscal year 2018Operating cash flow−75.5Capital expenditure−3.8Free cash flow−79.3 −147.0%Fiscal year 2019Operating cash flow−140.5Capital expenditure−3.5Free cash flow−144.0Fiscal year 2020Operating cash flow5.3Capital expenditure−2.3Free cash flow3.0Fiscal year 2021Operating cash flow−119.0Capital expenditure−1.6Free cash flow−120.6 −4,189.5%Fiscal year 2022Operating cash flow−110.8Capital expenditure−1.7Free cash flow−112.5Fiscal year 2023Operating cash flow−56.0Capital expenditure−0.8Free cash flow−56.9Fiscal year 2024Operating cash flow−86.2Capital expenditure−0.3Free cash flow−86.5Fiscal year 2025Operating cash flow−75.6Capital expenditure−0.2Free cash flow−75.8
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −2.0 170.4 −75.5 −140.5 5.3 −119.0 −110.8 −56.0 −86.2 −75.6
Capital expenditure −2.2 −1.6 −3.8 −3.5 −2.3 −1.6 −1.7 −0.8 −0.3 −0.2
Free cash flow −4.2 168.8 −79.3 −144.0 3.0 −120.6 −112.5 −56.9 −86.5 −75.8
Growth −147.0% −4,189.5%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash104.6Shareholders’ equity78.5Fiscal year 2017Cash177.5Shareholders’ equity69.9Fiscal year 2018Cash247.6Shareholders’ equity135.8Fiscal year 2019Cash188.4Shareholders’ equity25.5Fiscal year 2020Cash191.9Shareholders’ equity−7.8Fiscal year 2021Cash205.5Shareholders’ equity−0.5Fiscal year 2022Cash193.7Shareholders’ equity−85.8Fiscal year 2023Cash17.2Shareholders’ equity−47.4Fiscal year 2024Cash38.1Shareholders’ equity−0.5Fiscal year 2025Cash12.7Shareholders’ equity99.0
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 104.6 177.5 247.6 188.4 191.9 205.5 193.7 17.2 38.1 12.7
Shareholders’ equity 78.5 69.9 135.8 25.5 −7.8 −0.5 −85.8 −47.4 −0.5 99.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
12.8 71.6 59.5 26.9 68.4 37.3 53.2 101.2 138.1 76.2
Growth +457.6% −16.9% −54.8% +154.4% −45.5% +42.5% +90.4% +36.4% −44.8%
54.8 92.3 103.9 131.6 112.9 114.2 111.6 77.7 83.4 68.7
19.9 25.6 33.5 36.8 36.0 39.2 42.8 30.0 29.7 29.8
−59.6 −46.3 −77.9 −141.5 −80.5 −116.0 −101.3 −6.5 25.0 −22.4
Growth −189.5%
−58.9 −43.6 −70.3 −133.3 −78.7 −115.9 −99.3 3.3 32.1 −17.1
−0.0 −0.5 14.3 −0.4 −13.9 0.0 0.0 3.9 0.2 0.2
−58.9 −43.1 −84.6 −132.8 −64.8 −115.9 −99.3 −0.6 31.9 −17.4
Growth −154.5%
Per share
n/a n/a n/a −2.93 −1.40 −1.81 −1.51 −0.01 0.38 −0.15
n/a n/a n/a −2.93 −1.40 −1.81 −1.51 −0.01 0.38 −0.15
Growth −139.5%
n/a n/a n/a 45.3 46.1 64.1 65.7 73.8 84.4 137.9
n/a n/a n/a 45.3 46.1 64.1 65.7 73.8 84.7 137.9
Growth +1.8% +39.0% +2.5% +12.3% +14.8% +62.8%

† The diluted share count jumps at 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 2.2% a year over five years.
  • Operating margin is up 88.4 points on five years ago, at -29.3%.
  • A net loss in 9 of 10 years on file.